Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders
Rainer Rupprecht
1, 2
,
Vassilios Papadopoulos
3
,
Gerhard Rammes
2, 4
,
Thomas C. Baghai
1
,
Jinjiang Fan
3
,
Nagaraju Akula
5
,
Ghislaine Groyer
6
,
David Adams
7
,
Michael Schumacher
6
3
7
Department of Neurology, Bicêtre Hospital, Assistance Publique des Hôpitaux de Paris, France
|
Publication type: Journal Article
Publication date: 2010-12-01
scimago Q1
wos Q1
SJR: 30.506
CiteScore: 181.8
Impact factor: 101.8
ISSN: 14741776, 14741784
DOI:
10.1038/nrd3295
PubMed ID:
21119734
Drug Discovery
General Medicine
Pharmacology
Abstract
The expression of TSPO, a mitochondrial translocator protein involved in steroid synthesis, in the nervous system is altered in numerous neurological and psychiatric conditions. Rupprecht and colleagues review the potential of TSPO ligands for the treatment and diagnosis of disorders including anxiety, neuropathic pain and amyotrophic lateral sclerosis. The translocator protein (18 kDa) (TSPO) is localized primarily in the outer mitochondrial membrane of steroid-synthesizing cells, including those in the central and peripheral nervous system. One of its main functions is the transport of the substrate cholesterol into mitochondria, a prerequisite for steroid synthesis. TSPO expression may constitute a biomarker of brain inflammation and reactive gliosis that could be monitored by using TSPO ligands as neuroimaging agents. Moreover, initial clinical trials have indicated that TSPO ligands might be valuable in the treatment of neurological and psychiatric disorders. This Review focuses on the biology and pathophysiology of TSPO and the potential of currently available TSPO ligands for the diagnosis and treatment of neurological and psychiatric disorders.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
30
|
|
|
International Journal of Molecular Sciences
27 publications, 3.39%
|
|
|
Journal of Neuroinflammation
14 publications, 1.76%
|
|
|
Brain, Behavior, and Immunity
12 publications, 1.51%
|
|
|
European Journal of Nuclear Medicine and Molecular Imaging
11 publications, 1.38%
|
|
|
Neuropharmacology
11 publications, 1.38%
|
|
|
Journal of Medicinal Chemistry
10 publications, 1.26%
|
|
|
Journal of Nuclear Medicine
9 publications, 1.13%
|
|
|
Psychoneuroendocrinology
9 publications, 1.13%
|
|
|
Neuroscience and Biobehavioral Reviews
9 publications, 1.13%
|
|
|
Molecular Psychiatry
8 publications, 1.01%
|
|
|
Journal of Neuroendocrinology
8 publications, 1.01%
|
|
|
Molecular Pharmaceutics
8 publications, 1.01%
|
|
|
Journal of Neuroscience
8 publications, 1.01%
|
|
|
Journal of Cerebral Blood Flow and Metabolism
7 publications, 0.88%
|
|
|
PLoS ONE
7 publications, 0.88%
|
|
|
European Journal of Medicinal Chemistry
7 publications, 0.88%
|
|
|
Biochemical Society Transactions
6 publications, 0.75%
|
|
|
Frontiers in Cellular Neuroscience
6 publications, 0.75%
|
|
|
Frontiers in Pharmacology
6 publications, 0.75%
|
|
|
Molecular Neurobiology
6 publications, 0.75%
|
|
|
Psychopharmacology
6 publications, 0.75%
|
|
|
Molecular Imaging and Biology
6 publications, 0.75%
|
|
|
Frontiers in Neuroendocrinology
6 publications, 0.75%
|
|
|
Biochimica et Biophysica Acta - Molecular Basis of Disease
6 publications, 0.75%
|
|
|
Biochimie
6 publications, 0.75%
|
|
|
Endocrinology
5 publications, 0.63%
|
|
|
Scientific Reports
5 publications, 0.63%
|
|
|
Neuropsychopharmacology
5 publications, 0.63%
|
|
|
European Journal of Pharmacology
5 publications, 0.63%
|
|
|
5
10
15
20
25
30
|
Publishers
|
50
100
150
200
250
|
|
|
Elsevier
248 publications, 31.16%
|
|
|
Springer Nature
142 publications, 17.84%
|
|
|
Wiley
68 publications, 8.54%
|
|
|
MDPI
47 publications, 5.9%
|
|
|
Frontiers Media S.A.
39 publications, 4.9%
|
|
|
American Chemical Society (ACS)
35 publications, 4.4%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
20 publications, 2.51%
|
|
|
Taylor & Francis
18 publications, 2.26%
|
|
|
Cold Spring Harbor Laboratory
13 publications, 1.63%
|
|
|
SAGE
12 publications, 1.51%
|
|
|
Portland Press
11 publications, 1.38%
|
|
|
Oxford University Press
11 publications, 1.38%
|
|
|
Royal Society of Chemistry (RSC)
10 publications, 1.26%
|
|
|
Society of Nuclear Medicine
9 publications, 1.13%
|
|
|
Public Library of Science (PLoS)
8 publications, 1.01%
|
|
|
Society for Neuroscience
8 publications, 1.01%
|
|
|
Bentham Science Publishers Ltd.
7 publications, 0.88%
|
|
|
The Endocrine Society
7 publications, 0.88%
|
|
|
Hindawi Limited
6 publications, 0.75%
|
|
|
American Society for Biochemistry and Molecular Biology
5 publications, 0.63%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
4 publications, 0.5%
|
|
|
Pleiades Publishing
4 publications, 0.5%
|
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 0.5%
|
|
|
Georg Thieme Verlag KG
4 publications, 0.5%
|
|
|
American Medical Association (AMA)
4 publications, 0.5%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
3 publications, 0.38%
|
|
|
Society for the Study of Reproduction
3 publications, 0.38%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
3 publications, 0.38%
|
|
|
Bioscientifica
2 publications, 0.25%
|
|
|
50
100
150
200
250
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
796
Total citations:
796
Citations from 2025:
42
(5.28%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Rupprecht R. et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders // Nature Reviews Drug Discovery. 2010. Vol. 9. No. 12. pp. 971-988.
GOST all authors (up to 50)
Copy
Rupprecht R., Papadopoulos V., Rammes G., Baghai T. C., Fan J., Akula N., Groyer G., Adams D., Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders // Nature Reviews Drug Discovery. 2010. Vol. 9. No. 12. pp. 971-988.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/nrd3295
UR - https://doi.org/10.1038/nrd3295
TI - Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders
T2 - Nature Reviews Drug Discovery
AU - Rupprecht, Rainer
AU - Papadopoulos, Vassilios
AU - Rammes, Gerhard
AU - Baghai, Thomas C.
AU - Fan, Jinjiang
AU - Akula, Nagaraju
AU - Groyer, Ghislaine
AU - Adams, David
AU - Schumacher, Michael
PY - 2010
DA - 2010/12/01
PB - Springer Nature
SP - 971-988
IS - 12
VL - 9
PMID - 21119734
SN - 1474-1776
SN - 1474-1784
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2010_Rupprecht,
author = {Rainer Rupprecht and Vassilios Papadopoulos and Gerhard Rammes and Thomas C. Baghai and Jinjiang Fan and Nagaraju Akula and Ghislaine Groyer and David Adams and Michael Schumacher},
title = {Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders},
journal = {Nature Reviews Drug Discovery},
year = {2010},
volume = {9},
publisher = {Springer Nature},
month = {dec},
url = {https://doi.org/10.1038/nrd3295},
number = {12},
pages = {971--988},
doi = {10.1038/nrd3295}
}
Cite this
MLA
Copy
Rupprecht, Rainer, et al. “Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.” Nature Reviews Drug Discovery, vol. 9, no. 12, Dec. 2010, pp. 971-988. https://doi.org/10.1038/nrd3295.